Goldman Sachs Group Inc. Trims Holdings in LeMaitre Vascular Inc (LMAT)

Goldman Sachs Group Inc. reduced its position in shares of LeMaitre Vascular Inc (NASDAQ:LMAT) by 21.3% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 49,796 shares of the medical instruments supplier’s stock after selling 13,449 shares during the quarter. Goldman Sachs Group Inc. owned about 0.26% of LeMaitre Vascular worth $1,586,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in LMAT. Bank of New York Mellon Corp increased its holdings in LeMaitre Vascular by 3.6% during the 3rd quarter. Bank of New York Mellon Corp now owns 218,118 shares of the medical instruments supplier’s stock worth $8,161,000 after purchasing an additional 7,490 shares during the period. Ameriprise Financial Inc. increased its holdings in LeMaitre Vascular by 29.0% during the 3rd quarter. Ameriprise Financial Inc. now owns 199,273 shares of the medical instruments supplier’s stock worth $7,457,000 after purchasing an additional 44,801 shares during the period. Legal & General Group Plc increased its holdings in LeMaitre Vascular by 18.7% during the 3rd quarter. Legal & General Group Plc now owns 27,419 shares of the medical instruments supplier’s stock worth $1,027,000 after purchasing an additional 4,323 shares during the period. Wells Fargo & Company MN increased its holdings in LeMaitre Vascular by 17.8% during the 3rd quarter. Wells Fargo & Company MN now owns 134,482 shares of the medical instruments supplier’s stock worth $5,032,000 after purchasing an additional 20,296 shares during the period. Finally, Schwab Charles Investment Management Inc. increased its holdings in LeMaitre Vascular by 124.7% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 65,477 shares of the medical instruments supplier’s stock worth $2,451,000 after purchasing an additional 36,342 shares during the period. Institutional investors own 72.76% of the company’s stock.

How to Become a New Pot Stock Millionaire

Shares of NASDAQ:LMAT opened at $40.72 on Thursday. LeMaitre Vascular Inc has a 12-month low of $24.95 and a 12-month high of $41.25. The firm has a market capitalization of $788.60, a PE ratio of 47.35, a P/E/G ratio of 2.79 and a beta of 0.54.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Wednesday, February 21st. The medical instruments supplier reported $0.21 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.20 by $0.01. LeMaitre Vascular had a return on equity of 16.93% and a net margin of 17.03%. The business had revenue of $26.15 million for the quarter, compared to the consensus estimate of $26.23 million. During the same period last year, the business posted $0.13 EPS. The business’s revenue was up 12.3% compared to the same quarter last year. sell-side analysts anticipate that LeMaitre Vascular Inc will post 0.98 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Thursday, April 5th. Stockholders of record on Thursday, March 22nd were issued a $0.07 dividend. The ex-dividend date of this dividend was Wednesday, March 21st. This is an increase from LeMaitre Vascular’s previous quarterly dividend of $0.06. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.69%. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 32.56%.

Several research analysts have commented on the company. BidaskClub upgraded LeMaitre Vascular from a “sell” rating to a “hold” rating in a report on Wednesday, January 31st. ValuEngine upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Wednesday, April 4th. Zacks Investment Research upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating and set a $40.00 price target on the stock in a report on Wednesday, February 28th. Finally, Canaccord Genuity reiterated a “hold” rating and issued a $33.00 price target on shares of LeMaitre Vascular in a report on Friday, February 23rd. Four equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. LeMaitre Vascular presently has a consensus rating of “Buy” and an average price target of $34.00.

In other news, CEO George W. Lemaitre sold 42,036 shares of LeMaitre Vascular stock in a transaction on Monday, February 26th. The stock was sold at an average price of $35.68, for a total value of $1,499,844.48. Following the transaction, the chief executive officer now directly owns 3,259,263 shares in the company, valued at approximately $116,290,503.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Chairman George W. Lemaitre sold 45,000 shares of the firm’s stock in a transaction on Monday, March 5th. The stock was sold at an average price of $34.66, for a total value of $1,559,700.00. Following the completion of the sale, the chairman now directly owns 3,225,709 shares of the company’s stock, valued at approximately $111,803,073.94. The disclosure for this sale can be found here. Insiders sold a total of 137,736 shares of company stock worth $4,866,186 over the last quarter. Company insiders own 23.70% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Goldman Sachs Group Inc. Trims Holdings in LeMaitre Vascular Inc (LMAT)” was originally reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright laws. The original version of this piece can be viewed at https://www.thelincolnianonline.com/2018/04/19/goldman-sachs-group-inc-trims-holdings-in-lemaitre-vascular-inc-lmat.html.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.

Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LeMaitre Vascular Inc (NASDAQ:LMAT).

Institutional Ownership by Quarter for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply